Fresolimumab is a humanized monoclonal antibody targeting TGFβ1, TGFβ2, and TGFβ3, developed for the treatment of advanced melanoma and renal cell carcinoma; it has also been investigated in patients with primary brain tumors (astrocytoma and glioblastoma) using 89Zr-GC1008 PET imaging to quantify tumor uptake; additionally, it is being evaluated in combination with radiotherapy for the treatment of stage IA-IB non-small cell lung cancer in a Phase I/II clinical trial.